Redeye sees another quarter where AroCell delivers sales relatively in line with our estimates and continue to have good cost control. Nothing new has been communicated regarding its strategic overview, and we do not expect to hear much until there is more concrete information. We lower our sales forecast somewhat and increase our WACC, rendering a lowered fair value range.